Conference Coverage

Guselkumab achieves highest-ever response rates in psoriasis


 

Pages

Recommended Reading

Psoriatic arthritis patients face more endocrine comorbidities
MDedge Rheumatology
SHARE initiative releases consensus-based JDM management recommendations
MDedge Rheumatology
Psoriasis cardiovascular risk parallels type 2 diabetes
MDedge Rheumatology
Ixekizumab improved psoriatic arthritis in patients who had not taken biologics
MDedge Rheumatology
Biosimilar version of etanercept gains FDA approval
MDedge Rheumatology
Tips on how to differentiate CLE from dermatomyositis
MDedge Rheumatology
Be alert for dermatomyositis without muscle disease
MDedge Rheumatology
Psoriasis not consistently linked to adverse pregnancy outcomes
MDedge Rheumatology
Birth outcomes unaffected by paternal immunosuppressive therapy
MDedge Rheumatology
FDA approves biosimilar adalimumab
MDedge Rheumatology